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ABSTRACT
Long interspersed element-1 (LINE-1, L1) composes
∼17% of the human genome. However, genetic inter-
actions between L1 and human immunodeficiency
virus type 1 (HIV-1) remain poorly understood. In this
study, we found that HIV-1 suppresses L1 retrotrans-
position. Notably, HIV-1 Vpr strongly inhibited retro-
transposition without inhibiting L1 promoter activity.
Since Vpr is known to regulate host cell cycle, we
examined the possibility whether Vpr suppresses L1
retrotransposition in a cell cycle dependent manner.
We showed that the inhibitory effect of a mutant Vpr
(H71R), which is unable to arrest the cell cycle, was
significantly relieved compared with that of wild-type
Vpr, suggesting that Vpr suppresses L1 mobility in
a cell cycle dependent manner. Furthermore, a host
cell cycle regulator p21Waf1 strongly suppressed L1
retrotransposition. The N-terminal kinase inhibitory
domain (KID) of p21 was required for this inhibitory
effect. Another KID-containing host cell cycle regu-
lator p27Kip1 also strongly suppressed L1 retrotrans-
position. We showed that Vpr and p21 coimmuno-
precipitated with L1 ORF2p and they suppressed the
L1 reverse transcriptase activity in LEAP assay, sug-
gesting that Vpr and p21 inhibit ORF2p-mediated re-
verse transcription. Altogether, our results suggest
that viral and host cell cycle regulatory machinery
limit L1 mobility in cultured cells.
INTRODUCTION
Long interspersed element-1 (LINE-1, L1) is an active and
autonomous non-long terminal repeat (LTR) retrotranspo-
son composing ∼17% of the human genome (1–3). L1 en-
codes two open reading frames (ORFs), ORF1p with RNA
binding domain and nucleic acid chaperone activity, and
ORF2p with endonuclease and reverse transcriptase activ-
ities required for its retrotransposition (1,2,4,5). L1 tran-
scription occurs through promoter activity located in its
5′UTR (6). Several transcription factors including p53 (7),
RUNX3 (8), SOX11 (9) and YY1 (10,11) positively regu-
late the L1 transcription (12). On the other hand, SRY (9)
and SOX2 (13) negatively regulate the L1 transcription. L1
RNAassembles withORF1p andORF2p to form a ribonu-
cleoprotein (RNP) complex in the cytoplasm (14). Then,
L1-RNP complex enters the nucleus in which genomic in-
tegration occurs by a mechanism termed target-primed re-
verse transcription (TPRT). During TPRT, the L1 endonu-
clease creates a nicked DNA that serves as a primer for re-
verse transcription of L1 RNA, leading to integration of L1
cDNA into the human genome (15). Although L1 expres-
sion and retrotransposition can occur during early embryo-
genesis (16–18) and gametogenesis (18,19), L1 transcription
is largely repressed by DNA methylation in somatic cells
(19,20). In addition to the epigenetic control of L1 expres-
sion, L1 retrotransposition is controlled by several host re-
striction factors such as APOBEC3G (A3G), APOBEC3F
(A3F) and MOV10 (12,21–27). A3G was first identified as
anti-human immunodeficiency virus type 1 (HIV-1) restric-
tion factor (28) andHIV-1 restriction requires A3G cytidine
deaminase activity (29,30). A3G restricts exogenous retro-
viruses, hepatitis B virus (HBV), and endogenous retroele-
ments, such as L1, Alu, SVA and HERVs (21,29,31–34).
However, the A3G cytidine deaminase activity is dispens-
able for L1 restriction. Escape of these control pathways
can lead to de novo L1 retrotransposition in somatic cells
that could contribute to mutagenesis and genomic instabil-
ity leading to cancer (35–38). L1 retrotransposition can also
generatemutations of genes in the germ line or during devel-
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opment that could contribute to diseases (39,40). Therefore,
L1 must be regulated during normal development.
HIV-1 is a retrovirus, which encodes three structural pro-
teins, group-specific antigen (Gag), polymerase (Pol), and
envelope (Env), two regulatory proteins, Tat and Rev, and
four accessory proteins, Vif, Vpu, Vpr and Nef. The gene
expression of HIV-1 is transcriptionally regulated by Tat
through its binding to a nascent HIV-1 trans-activation re-
sponsive (TAR) RNA (41,42), and post-transcriptionally
by Rev through its interaction with Rev-responsive element
(RRE) RNA in the env gene (43–45). Rev forms a complex
with CRM1-Ran-GTP and enhances the nuclear export of
HIV-1 mRNA (43–45). In addition, several host DEAD-
box RNA helicases cooperate to modulate HIV-1 Rev func-
tion (46–50). HIV-1 Vpr is a virion-associated nuclear pro-
tein with multiple functions (51,52). Vpr facilitates HIV-1
infection of nondividing cells by regulating the nuclear ex-
port of the HIV-1 pre-integration complex (PIC). Vpr also
induces cell cycle arrest at the G2 phase in proliferating in-
fected cells and stimulates the LTR-directed gene expression
(53). Following HIV-1 entry, its own reverse transcriptase
synthesizes a DNA copy of the HIV-1 genomic RNA. Inte-
gration of a DNA copy of the viral RNA genome is a cru-
cial step in the life cycle of HIV-1. Therefore, both HIV-1
and L1 might mutually influence their mobility. However,
interactions betweenHIV-1 andL1 are notwell understood.
Therefore, we investigated a cross talk of HIV-1 with L1 in
this study.
MATERIALS AND METHODS
Cell culture
293T, TET293T, P4.2 and TZM-bl cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Life Tech-
nology, Carlsbad, CA, USA) with high glucose (4.5 g/l)
supplemented with 10% fetal bovine serum (FBS) and 100
U/ml penicillin/streptomycin. Details of specific transfec-
tion conditions for each experiment are provided in the fig-
ure legends.
Plasmid construction
To construct pcDNA3-HA-ORF1 or pcDNA3-ORF1-
HA, a DNA fragment encoding ORF1p was amplified
from pEGFP-L1RP wt (54) by PCR using KOD-Plus
DNA polymerase (TOYOBO, Osaka, Japan) and the
following pairs of primers: HA-ORF1, 5′-CGGGATC
CAAGATGGGGAAAAAACAGAACA-3′ (Forward),
5′-CCG GCGGCCGCTTACATTTTGGCATGATTT-3′
(Reverse); ORF1-HA, 5′-CG GGATCCAAGATG
GGGAAAAAACAGAACA-3′ (Forward), 5′-CCG
GCGGCCGCTTAAGAAGGTCCTCCCAGGCTGGC
ATAGTCAGGCACGTCATAAGGATAGCTAGAAG
CCATCATTTTGGCATGATTTTG-3′ (Reverse). The
obtained DNA fragments were subcloned into either
the BamHI–XhoI sites of the pcDNA3-HA vector or
the BamHI–NotI sites of the pcDNA3 vector (Invit-
rogen), and the nucleotide sequences were determined
by Sanger sequencing. To construct pcDNA3-FLAG-
ORF1, the DNA fragments encoding ORF1 obtained
by digestion with BamHI and XhoI were subcloned
into the BamHI-XhoI sites of the pcDNA3-FLAG
vector. To construct pcDNA3-HA-Vpr WT, pcDNA3-
HA-Vpr H71R, or pEGFP-Vpr, a DNA fragment
encoding HIV-1 Vpr was amplified from pCMX Vpr96
by PCR using KOD-Plus DNA polymerase and the fol-
lowing pairs of primers: HA-Vpr WT, 5′-CGGGATC
CAAGATGGAACAAGCCCCAGAAG-3′ (Forward),
5′-CCGGCGGCCGCCTAGGATCTACTGGCTCCA-3′
(Reverse); HA-Vpr H71K, 5′-CGGGATCCAAGAT
GGAACAAGCCCCAGAAG-3′ (Forward), 5′-CCG
GCGGCCGCCTAGGATCTACTGGCTCCATTTCT
TGCTCTCCTCTGTCGAGTAACGCCTATTCTGCTA
TGTCGACACCCAATTCTGAAACGGATAAACA-3′
(Reverse); EGFP-Vpr, 5′-CGCTCGAGAAG
ATGGAACAAGCCCCAGAAG-3′ (Forward),
5′-CGGGATCCCTAGGATCTACTGGCTCCATTT-3′
(Reverse). The obtained DNA fragments were subcloned
into the BamHI–NotI sites of the pcDNA3-HA vector
or the XhoI–BamHI sites of the pEGFP-C3 (Promega).
To construct pAIP-Vpr WT or pAIP-Vpr H71R, a DNA
fragment encoding Vpr WT or H71R was amplified from
pcDNA3-HA-Vpr WT or pcDNA3-HA-Vpr H71R by
TKs Gflex DNA polymerase (TAKARA) and the follow-
ing pair of primers: 5′-TCTCTCCCCATCTAGATGG
AACAAGCCCCAGAAGAC-3′ (Forward), 5′-GCGTT
TAAACGGATCCTAGGATCTACTGGCTCCATT-3′
(Reverse). The obtained DNA fragments were subcloned
into the BamHI–XbaI sites of pAIP (55) by using In-
Fusion Cloning kit (Clonetech). pcDNA3p21 and p21N
were kindly provided by Dr. Dutta (56). To construct
pcDNA3p21C, a DNA fragment encoding p21C was am-
plified from pcDNA3p21 by PCR using KOD-Plus DNA
polymerase and the following pairs of primers: 5′-CGGGA
TCCAAGATGCGAGGCCGGGATGAGT-3′ (Forward),
5′-CCGCTCGAGTTAGGGCTTCCTCTTGGAGAA-3′
(Reverse). The obtained DNA fragments were subcloned
into the BamHI–XhoI sites of the pcDNA3-HA vector.
RNA interference
Oligonucleotides with the following sense and antisense
sequences were used for the cloning of short hairpin RNA
(shRNA)-encoding sequences targeted to p21 in a lentiviral
vector: 5′-GATCCCCGACCATGTGGACCTGTCACT
TCAAGAGAGTGACAGGTCCACATGGTCTTTTT
GGAAA-3′ (sense), 5′-AGCTTTTCCAAAAAGACCA
TGTGGACCTGTCACTCTCTTGAAGTGACAGGT
CCACATGGTCGGG-3′ (antisense). The oligonucleotides
above were annealed and subcloned into the BglII–HindIII
sites, downstream from an RNA polymerase III promoter
of pSUPER (57), to generate pSUPER-p21i. To construct
pLV-p21i, the BamHI–SalI fragment of the pSUPER-p21i
was subcloned into the BamHI–SalI sites of pRDI292, an
HIV-1-derived self-inactivating lentiviral vector containing
a puromycin resistance marker allowing for the selection of
transduced cells (58).
Lentiviral vector production
The vesicular stomatitis virus (VSV)-G-pseudotyped HIV-
1-based vector system has been described previously
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(59,60). The lentiviral vector particles were produced by
transient transfection of the second-generation packaging
construct pCMVR8.74 (59,60) and the VSV-G-envelope-
expressing plasmid pMD2G as well as lentiviral vector
pLV-p21i or pAIP (55) into 293T cells with FuGENE6
(Promega,Madison,WI, USA) or TransIT-LT1 (Mirus Bio
LLC, Madison, WI 53711, USA) transfection reagents.
HIV-1 infection
Different full-lengthHIV-1molecular clones used for trans-
fection were as follows: pR9 (59,60), pNL4-3 (61), pJR-FL
(62) and pAD8 (63). Recombinant HIV-1 was prepared as
described previously (64). Briefly, 293T cells were used as
viral producer cells. The cells were seeded at 2 × 105 cells
per well into six-well tissue culture plates and transfected
the next day using TransIT-LT1 reagent with one of the fol-
lowing HIV-1 molecular clones: pR9, pNL4-3, pJR-FL or
pAD8. Culture media were replaced with fresh media 24 h
after transfection, and the cells were cultured for an ad-
ditional 48 h. Then, the supernatants containing recombi-
nant viruses were clarified by centrifugation and filtration
with 0.45 m filter (Kurabo, Osaka, Japan), and stored at
−80◦C before use. Released HIV-1 virions were collected by
centrifugation of the culture supernatants from transfected
293T cells at 20 000× g for 2 h at 4◦C.The pellets containing
virions were dissolved in the lysis buffer and then subjected
towestern blot.HIV-1 infectionwas performed as described
previously (64). P4.2, CD4+ HeLa cells were incubated with
the supernatants of 293T cells containing HIV-1 at the in-
dicated multiplicity of infection (MOI), and the cells were
cultured for an additional 48h.
Western blot analysis
Cells were lysed in buffer containing 50 mM Tris–HCl
(pH 8.0), 150 mM NaCl, 4 mM EDTA, 1% Nonidet (N)
P-40, 0.1% sodium dodecyl sulfate (SDS), 1 mM dithio-
threitol (DTT) and 1 mM phenylmethylsulfonyl fluoride
(PMSF). Supernatants from these lysates were subjected
to SDS-polyacrylamide gel electrophoresis, followed by im-
munoblot analysis using anti-HIV-1 p24 (65-005; Bioa-
cademia, Osaka, Japan), anti-p21Waf1/Cip1 (12D1) (#2947;
Cell Signaling Technology, Inc., Danvers, MA 01923,
USA), anti-p21 [EPR362] (ab 109520; Abcam), anti--
actin (A5441; Sigma, Saint Louis, MI, USA), anti-HA
(HA-7; Sigma), anti-HA (12CA5; Santa Cruz), anti-FLAG
antibody (M2; Sigma), anti-S6 ribosomal protein (5G10;
Cell Signaling Technology), anti-GAPDH (GA1R, Pierce
Biotechnology), anti-hrGFP (#240141, Agilent Technolo-
gies), or anti-hORF1p (SE-6798) (65) as primary antibod-
ies. We used peroxidase-conjugated Donkey anti-Rabbit
IgG (H+L) (Jackson ImmunoResearch), Amersham ECL
peroxidase-linked Sheep anti-Mouse IgG (GEHealthcare),
IRDye 800CWGoat anti-Rabbit IgG, IRDye 800CWGoat
anti-Mouse IgG, IRDye 680RD Goat anti-Rabbit IgG
or IRDye 680RD Goat anti-Mouse IgG (LI-COR Bio-
sciences) as secondary antibodies.
Luciferase assay
293T cells were seeded in 24-well plates at 2 × 104 cells per
plate and then transfected the next day with plasmids us-
ing FuGENE6 (Promega, Madison, WI, USA) or TransIT-
LT1 transfection reagent. Luciferase assays were performed
72 h after transfection using luciferase assay reagent ac-
cording to the manufacturer’s instructions (Promega). All
transfections were performed using equal number of tested
plasmid DNAmolecules, with the addition of empty vector
into the transfection mixtures to compensate for plasmid
size differences and reach equal amounts of DNA quan-
tities per condition. Results were obtained through three
independent transfections. A Lumat LB9507 luminometer
(Berthold, Bad Wildbad, Germany) was used to measure
luciferase activities.
Cell cycle analysis
For cell cycle analysis, cells were fixed in 70% ethanol at 4◦C
overnight and stained with propidium iodide (PI, 10g/ml)
(66). The DNA content in each cell was analyzed on LSRII
flow cytometer (BD Bioscience, San Jose, CA). Data were
analyzed on Flowjo software (Tree Star, San Carlos, CA)
Immunoprecipitation
Cells were lysed in buffer containing 10 mM Tris–HCl (pH
8.0), 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 10 mM
NaF, 1 mM DTT and 1 mM PMSF. Lysates were pre-
cleared with 30 l of protein-G-Sepharose (GE Healthcare
Bio-Sciences, Uppsala, Sweden). Pre-cleared supernatants
were incubated with 5g of either anti-HA antibody (3F10;
Roche Diagnostics, Mannheim, Germany) or anti-FLAG
antibody (M2, Sigma) at 4◦C for 1 h. Following absorption
of the precipitates on 30 l of protein-G-Sepharose resin
for 1 h, the resin was washed four times with 700 l of lysis
buffer. Proteins were eluted by boiling the resin for 5 min
in 2× Laemmli sample buffer. The proteins were then sub-
jected to SDS-PAGE, followed by immunoblot analysis.
Immunofluorescence and confocal microscopy analysis
293T cells were grown on Lab-Tek 2 well chamber slide
(Nunc, Thermo) at 2× 104 cells per well and transfected the
next days using TransIT-LT1 transfection reagent. Two days
after transfection, the cells were fixed in 3.6% formalde-
hyde in 1× phosphate-buffered saline (PBS), permeabi-
lized in 0.1% NP-40 in 1× PBS at room temperature, and
incubated with anti-HA antibody (HA-7) at a 1:300 di-
lution in 1× PBS containing 3% bovine serum albumin
(BSA) at 37◦C for 30 min. Cells were then stained with
Cy3-conjugated anti-mouse antibody (Jackson ImmunoRe-
search, West Grove, PA, USA) at a 1:300 dilution in 1×
PBS containing 3% BSA at 37◦C for 30 min. Nuclei were
stained with DAPI (4′,6′-diamidino-2-phenylindole). Fol-
lowing washing three times in 1× PBS, the coverslides were
mounted on slides using SlowFade Gold antifade reagent
(Life Technology). Samples were analyzed under a confo-
cal laser-scanning microscope (FV1200; Olympus, Tokyo,
Japan).
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Real-time RT-PCR
Total RNA was isolated using RNeasy Mini kit (Qiagen)
and treated with Turbo DNA-free kit (Life Technology).
The total RNAwas reverse transcribed with oligo(dT)12-18
primer (Life Technology). The quantitative RT-PCR anal-
ysis for LINE-1 mRNA was performed by real-time Light-
Cycler PCR (Roche). We used the following forward and
reverse primer sets:
5UTR L1 Hs, GGGAGGAGGAGCCAAGATG
(Forward), ACACTGGCCTGCGCCCACTG (Reverse);
ORF1 L1 Hs, AAAACGCAGAGCGCCTCTCC (For-
ward), GTTTGAATGTCCTCCCGTAG (Reverse);
ORF1 L1PA, GAACGCCACAAAGATACTCC (For-
ward), CTCTTCTGGCTTGTAGGGTTTCTG (Reverse);
β-actin, TGACGGGGTCACCCACACTG (forward),
AAGCTGTAGCCGCGCTCGGT (reverse).
Purification of L1 RNPs
L1 RNPs were prepared as previously described with mi-
nor modifications (65,67). Briefly, 293T cells were seeded
in 10 cm plates at 3 × 106 cells per plate and then trans-
fected the next days with 24 g of plasmid using the cal-
cium phosphate-mediated method (68). Culture medium
was changed 5h later. Cells were collected 5 days post-
transfection by trypsinization and were then lysed in
CHAPS extract buffer containing 10 mM Tris–HCl pH7.5,
0.5% CHAPS (w/v), 1 mM MgCl2, 1 mM EGTA, 10%
glycerol, protease inhibitors cocktail (Roche) and 1 mM
DTT. After incubation at 4◦C for 15 min, cell debris was
removed by centrifugation at 20 000 × g for 15 min. A su-
crose cushion was prepared with 8.5% and 17% (w/v) su-
crose in 20 mM Tris–HCl pH 7.5, 80 mM NaCl, 5 mM
MgCl2, 1 mM EGTA, protease inhibitors cocktail (Roche)
and 1 mMDTT. For each condition, 1 ml of cell lysate was
loaded on a sucrose cushion. Cellular RNPs were pelleted
by ultracentrifugation at 178 000 x g at 4◦C for 2 h. The pel-
lets were resuspended in 50 l of H2O. Quantification was
performed using the Bradford assay (Bio-rad). RNP frac-
tions were diluted at 1 g/l in H2O and aliquoted before
use or storage at −80◦C.
L1 element amplification protocol (LEAP) assay
LEAP assay was performed as previously described
(65,67,69). Briefly, L1 reverse transcription was carried
out at 37◦C for 1 h in 50 l reaction mixture contain-
ing 0.75 g of RNPs, 50 mM Tris–HCl pH 7.5, 50 mM
KCl, 5 mM MgCl2, 0.05% (v/v) Tween-20, 10 mM DTT,
20 U RNasin (Promega), 0.2 mM dNTPs and 0.4 M
RACE primer (5′-GCGAGCACAGAATTAATACGACT
CACTATAGGTTTTTTTTTTTTVN-3′).
1 l of the LEAP reaction were PCR-amplified
in 50 l reactions containing 0.2 mM dNTPs,
3 mM MgCl2, 10 pmol of primers LOU312 (5′-
GCGAGCACAGAATTAATACGACT-3′), LOU851
(5′-GGGTTCGAAATCGATAAGCTTGGATCCAGAC
-3′) and 2 U of Platinum Taq Polymerase (Life technolo-
gies). A first step at 94◦C for 2 min was followed by 35
cycles at 94◦C for 30 s, at 60◦C for 30 s and at 72◦C for 30 s
and by a final step at 72◦C for 5 min. The PCR products
were analyzed by 2% agarose gel electrophoresis in 0.5×
TBE buffer.
RNA extraction and RT-PCR
Total RNA was extracted from 15 g of L1 RNP fraction
using TRI reagent (MolecularResearchCenter Inc). DNase
treatment was performed at 37◦C for 30 min in a 10 l reac-
tionmixture containing 1g of extractedRNA, 1U ofRQ1
RNase-free DNase (Promega), 40 mMTris–HCl pH 8.0, 10
mMMgSO4 and 1 mM CaCl2. Then, cDNA synthesis was
performed at 50◦C for 1 h in 20l reactionmixture contain-
ing 6 l of DNase-treated RNA, 50 pmol of RACE primer,
10 nM dNTPs, 40 U RNaseOUT recombinant ribonucle-
ase inhibitor (Life Technologies), 200 U of SuperScript
III Reverse Transcriptase (Life technologies), 50 mM Tris–
HCl pH8.0, 75 mM KCl, 3 mM MgCl2 and 5 mM DTT.
After the first-strand cDNA synthesis, PCR amplification
was performed as described above but with only 30 cycles
of amplification and using primers LOU312 and LOU851
for L1, and LOU1071 (5′-GTTTTCCATTGGCTTGGTA
GATC-3′) and LOU1072 (5′-GAAGATGGTGATGGG
ATTTC-3′) for GAPDH.
Retrotransposition assays
LINE-1 retrotransposition assays consist of the expres-
sion in cells of a retrotransposition-competent L1 element
equipped with an indicator cassette for which the reporter
gene is expressed only after a cycle of retrotransposition
(54,70–72). The indicator cassette consists of a reporter
gene (e.g. EGFP, firefly luciferase) with its own promoter
and polyadenylation signal. It is introduced in the 3′UTR
of an active L1, in the opposite transcriptional orientation
compared to L1 (Figure 1A and B). The reporter gene is in-
terrupted by an intron with splice donor and splice acceptor
sites in the transcriptional orientation of the L1. Therefore,
the only way to express the reporter gene is when L1RNA is
expressed from its promoter, splicing occurs to remove the
intron, and then retrotransposition takes place, leading to
the insertion at a genomic locus of the reporter gene. In ab-
sence of the original intron, the reporter gene can now be
expressed from the integration site.
The EGFP-based retrotransposition assay was per-
formed as followed: 293T cells were seeded in 12-well plates
at 5 × 104 cells per plate and transfected the next day us-
ing FuGENE6 with 500 ng of either an EGFP-based retro-
transposition reporter pL1RP-EGFP (54) or its correspond-
ing negative control pL1RP(JM111)-EGFP which contains
two missense mutations (ARR at residues 260–262) in the
ORF1 coding region known to abolish retrotransposition
(54). Three days after transfection, retrotransposition effi-
ciency was determined by GFP fluorescence-activated cell
sorter (FACS) analysis with Guava easyCyte flow cytome-
ter (Merk Millipore, Billerica, MA, USA).
The luciferase-based retrotransposition assay was per-
formed using the firefly luciferase-based retrotransposition
reporter pYX014 plasmid (72). pYX014 is a dual-luciferase
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Figure 1. Suppression of L1 retrotransposition by HIV-1. (A) Schematic representation of the EGFP-based retrotransposition reporter cassette, pL1RP-
EGFP (54). The EGFP reporter is introduced in the 3′UTR of L1, in opposite orientation. It is also interrupted by an intron with splice donor (SD)
and splice acceptor (SA) in the transcriptional orientation of the L1. 293T cells (5 × 104 cells/well) were co-transfected with HIV-1 molecular clone
(R9, NL4-3 or JR-FL) (500 ng) and either pL1RP-EGFP or its mutant pL1RP(JM111)-EGFP lacking the ability of retrotransposition (500 ng). Three
days after transfection, retrotransposition efficiency was determined by GFP fluorescence-activated cell sorter (FACS) analysis with Guava easyCyte flow
cytometer (Merk Millipore, Billerica, MA, USA). Experiments were done in triplicate and graph shows the mean (±SEM) percentage of GFP positive
cells (*P < 0.05). (B) Schematic representation of the firefly luciferase-based retrotransposition reporter cassette, pYX014 (72). The pYX014 plasmid is
a dual-luciferase reporter, in which firefly luciferase is used as the retrotransposition indicator and Renilla luciferase is encoded on the same plasmid for
normalization. 293T cells (2 × 104 cells/well) were co-transfected with HIV-1 molecular clone (R9, NL4-3,or JR-FL) (100 ng) and pYX014 (100 ng) in
triplicate. Three days after transfection, luciferase assays were performed. Graph shows the mean (±SEM) firefly luciferase activity normalized withRenilla
luciferase activity with the condition without HIV-1 set to 100% (*P < 0.05). (C, D) Suppression of L1 retrotransposition by HIV-1 infection. P4.2 cells
(2 × 104 cells/well) were infected with either HIV-1 strain of R9 (C) or NL4-3 (D) at the indicated multiplicity of infection (MOI). 24h post-infection, the
HIV-1-infected cells were transfected with pYX014 (200 ng) in triplicate. Two days post-transfection, luciferase assays were performed. Graph shows the
mean (±SEM) firefly luciferase activity normalized with Renilla luciferase activity in Relative Luminometer Units (*P < 0.05).
reporter in which firefly luciferase is used as the retrotrans-
position indicator and Renilla luciferase is encoded on the
same plasmid backbone for normalization. 293T cells were
seeded in 24-well plates at 2 × 104 cells per plate and
then transfected the next day with pYX014 (100 ng) us-
ing TransIT-LT1 transfection reagent. Dual luciferase as-
says were performed 72 h after transfection using luciferase
assay reagent according to the manufacturer’s instructions
(Promega). A Lumat LB9507 luminometer (Berthold, Bad
Wildbad, Germany) was used to measure both firefly and
Renilla luciferase activities. Firefly luciferase activity was
normalized with Renilla luciferase activity.
Statistical analysis
The statistical significance of the inter-sample differences
was determined using the paired Student’s t test. P values
of <0.05 were considered statistically significant.
RESULTS
HIV-1 Vpr suppresses L1 retrotransposition
To investigate the potential role of HIV-1 expression in L1
retrotransposition, three different HIV-1 molecular clones
(R9, NL4-3 and JR-FL, respectively) (59–62) were co-
transfected in 293T cells with pL1RP-EGFP plasmid (Fig-
ure 1A), which contains an EGFP-based retrotransposition
reporter cassette in the antisense orientation (54). The pres-
ence of an intron in the opposite transcriptional orientation
of the reporter prevents EGFP expression from the plasmid.
GFP positive cells can only arise after expression, splicing
and retrotransposition of the labeled L1RP copy into new
genomic location. The use of a retrotransposition-deficient
L1 expressing plasmid, pL1RP(JM111)-EGFP, serves as
negative control of the assay (54). We analyzed by flow
cytometry the level of GFP expression and showed that
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all HIV-1 clones could strongly suppress the retrotranspo-
sition of L1 (Figure 1A). To confirm these findings, we
also assayed retrotransposition using the pYX014 plas-
mid, which has a firefly luciferase-based retrotransposi-
tion reporter cassette (72). The pYX014 plasmid is a dual-
luciferase reporter in which firefly luciferase is used as the
retrotransposition indicator and Renilla luciferase is en-
coded on the same plasmid backbone for normalization
(Figure 1B). Similar to the EGFP reporter, the firefly lu-
ciferase activity can only be detected once L1 retrotrans-
position occurred. Again, all HIV-1 clones could strongly
suppress the luciferase-based L1 retrotransposition activity
(Figure 1B). We next examined whether HIV-1 infection af-
fects L1 retrotransposition activity. CD4+HeLa P4.2 cells
were infected with HIV-1 (R9 or NL4-3) at the indicated
multiplicity of infection (MOI) (Figure 1C andD). The next
day, the luciferase-based retrotransposition reporter plas-
mid pYX014 was transfected into the HIV-1-infected cells.
Two days post-transfection, we measured luciferase activi-
ties and observed a three-fold reduction of L1 retrotranspo-
sition at the higherMOI for both R9 and NL4-3, indicating
that HIV-1 infection alsomodulates L1mobility (Figure 1C
and D). Since we did not infect equalized viral input (p24
amount) of HIV-1 between R9 and NL4-3 strains, the sup-
pression of L1 retrotransposition seems to vary based on
theMOI (Figure 1C andD). Subsequently, we used individ-
ual HIV-1 protein-expressing plasmids to determine which
of the following HIV-1 protein suppresses L1 retrotrans-
position: Vpr, Tat, Rev, integrase (IN), Env and Nef. Us-
ing the EGFP-based retrotransposition reporter, we showed
that only Vpr could strongly suppress L1 retrotransposition
(Figure 2A). We also noticed that Tat weakly suppress L1
retrotransposition (Figure 2A). Moreover, Vpr suppressed
L1 retrotransposition activity in a dose-dependent man-
ner (Figure 2B). Likewise, Vpr could strongly suppress the
luciferase-based L1 retrotransposition activity (Figure 2C).
To test if Vpr is affecting the L1 promoter activity, we
used pYX017 plasmid in which the L1RP 5′UTR (present
in pYX014) is replaced by a strong CAG promoter result-
ing in an increased retrotransposition activity (72) (Figure
2D). Despite the change of promoter, Vpr can also suppress
L1 retrotransposition when expressed from pYX017 (Fig-
ure 2D), suggesting that Vpr does not affect the endogenous
L1 promoter activity. Since HIV-1 Vpr is known to regulate
the host cell cycle by arresting cells at G2 phase (53), we
examined whether Vpr suppresses L1 retrotransposition in
a cell cycle dependent manner. To this end, we used a mu-
tant Vpr (H71R) unable to arrest cell cycle (53). Consistent
with the previous report, we confirmed that wild-type Vpr
(WT) arrested cell cycle at G2 (Figure 3A and B), while the
H71R mutant failed to arrest cell cycle (Figure 3C). As a
control, we observed similar levels of protein expression for
both Vpr (WT) and the mutant Vpr (H71R) in transfected
cells (Figure 3D). Although Vpr WT suppresses L1 retro-
transposition activities from both pYX014 and pYX017,
the inhibitory effect of Vpr (H71R) was significantly re-
lieved compared with that of Vpr (WT) (Figure 3E and F),
suggesting that Vpr suppresses L1 mobility in a cell cycle
dependent manner.
Figure 2. Suppression of LINE-1 retrotransposition by HIV-1 Vpr. (A)
293T cells (5× 104 cells/well) were co-transfectedwith eachHIV-1 protein-
expressing plasmid, Vpr, Tat, Rev, IN, Env or Nef (500 ng), and either
pL1RP-EGFP or pL1RP(JM111)-EGFP (500 ng). Three days after trans-
fection, retrotransposition efficiency was determined byGFPFACS analy-
sis. Experimentswere done in triplicate and graph shows themean (±SEM)
percentage of GFP positive cells (* P < 0.05). (B) Suppression of LINE-
1 retrotransposition by HIV-1 Vpr in a dose-dependent manner. 293T
cells (5 × 104 cells/well) were co-transfected with the indicated amounts
(ng) of pCMX-Vpr96 and either pL1RP-EGFP or pL1RP(JM111)-EGFP
(500 ng). Relative retrotransposition efficiency (fold) among three repli-
cates (±SEM) is shown (*P < 0.05). (C, D) 293T cells (2 × 104 cells/well)
were co-transfected with pCMX-Vpr96 (100 ng) and either pYX014 (C) or
pYX017 (100 ng) (D) in triplicate. Three days after transfection, luciferase
assays were performed. Graph shows the mean (±SEM) firefly luciferase
activity normalizedwithRenilla luciferase activity with the conditionwith-
out Vpr set to 100% (*P < 0.05).
p21Waf1 and p27 Kip1, host cell cycle regulators, suppress L1
retrotransposition
Since HIV-1 Vpr restricted L1 retrotransposition in a cell
cycle dependent manner (Figure 3), we examined whether
host cell cycle regulators, such as p21Waf1/Cip1 (p21) and p27
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Figure 3. Suppression of L1 retrotransposition by Vpr in a cell cycle dependent manner. (A–C) Cell cycle analysis of 293T cells expressing Vpr WT (B)
or Vpr H71R. (C). Cells were fixed in 70% ethanol three days post-transduction and stained with propidium iodide (PI) to perform cell cycle analysis
by FACS. (D) Protein expression levels of wild-type Vpr (WT) and a mutant Vpr (H71R). 293T cells (2 × 105 cells/well) were transfected with 2 g of
pcDNA3-HA-Vpr WT or pcDNA3-HA-Vpr H71R. Western blotting of cell lysates with anti-HA and anti--actin antibodies is shown. (E, F) 293T cells
(2 × 104 cells/well) were co-transfected with pYX014 (E) or pYX017 (100 ng) (F) and either pcDNA3-HA-Vpr WT or pcDNA3-HA-Vpr H71R (100 ng)
in triplicate. Three days after transfection, luciferase assays were performed. Graph shows the mean (±SEM) firefly luciferase activity normalized with
Renilla luciferase activity in Relative Luminometer Units (*P < 0.05).
Kip1 (p27) (73–77) might suppress L1 mobility. To test this
possibility, several plasmids expressing tumor suppressor-
related proteins were independently co-transfected with
pL1RP-EGFP plasmid into 293T cells. GFP fluorescence
was then analyzed by flow cytometry to monitor the impact
on L1 retrotransposition. Notably, p21 strongly suppressed
L1 retrotransposition (Figure 4A). p53 and p73, which tran-
scriptionally induce p21, also significantly suppressed L1
retrotransposition (Figure 4A). p21 has an N-terminal ki-
nase inhibitory domain (KID) and a C-terminal PCNA-
binding domain (Figure 4B) (56). Therefore, we used the N-
terminal half (p21N) or the C-terminal half of p21 (p21C)
to determine which domain is important for an inhibitory
effect on L1 retrotransposition (Figure 4B). Our results
showed that p21N but not p21C strongly suppressed L1
retrotransposition indicating that the kinase inhibitory do-
main is important for the inhibitory effect (Figure 4C and
D). In this regard, p21N is known to inhibit cell growth
whereas p21C does not (56). Consistent with this result, p27
harboring the kinase inhibitory domain also strongly sup-
pressed L1 retrotransposition (Figure 4C and D). To fur-
ther confirm this observation, we established a p21 knock-
down 293T cell line using lentiviral vector stably express-
ing shRNA targeted to p21 (p21KD in Figure 4E). As ex-
pected, the L1 retrotransposition efficiency was elevated in
p21 knockdown 293T cells (Figure 4F and G), even though
we observed no significant effect of p21 knockdown on the
293T cell growth. Thus, host cell cycle inhibitors p21 and
p27 restrict L1 mobility.
Incorporation of L1 ORF1p into HIV-1 virions
Since it has been indicated that several P-body and stress
granule components, such as APOBEC3G, APOBEC3F
and MOV10, are incorporated into HIV-1 virions and af-
fect HIV-1 infectivity or production (78–82), we examined
whether ORF1p is incorporated into HIV-1 virions and
modifies the HIV-1 infectivity. Notably, we noticed that
HA-tagged ORF1p (either in N- or C-terminus) are incor-
porated into the HIV-1 virions (NL4-3 and JR-FL), respec-
tively (Figure 5A). We also found that the incorporation
of ORF1p into HIV-1 virions was independent of HIV-1
accessory proteins including Nef, Vpr, Vpu and Vif, be-
cause the mutant viruses lacking the expression of each
viral gene still retained the ability to incorporate ORF1p
(Figure 5B). However, we failed to detect ORF2p and L1
RNA in HIV-1 virion (data not shown). On the other hand,
ORF1p affected neither the intracellular nor extracellular
HIV-1 p24 protein levels, suggesting that ORF1p does not
negatively impact HIV-1 replication (Figure 5A). Further-
more, the incorporated ORF1p-HA did not drastically af-
fect the HIV-1 infectivity, as measured by luciferase assay
with two independent infectious HIV-1 molecular clones
(NL4-3 and JR-FL) (61,62) (Figure 5C and D). However,
we noticed a modest suppressive effect of HA-ORF1 on
the infectivity of NL4-3 but not JR-FL. Since ORF1p is
an RNA-binding and nucleic acid chaperone protein, we
also examined whether ORF1p modulates the HIV-1 Tat-
mediated HIV-1 transcription using the HIV-1 LTR Luc re-
porter assay (83–85) or HIV-1 Rev-dependent nuclear ex-
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Figure 4. p21 and p27 suppress L1 retrotransposition. (A) Potential effect of tumor suppressor proteins on L1 retrotransposition. 293T cells (5 × 104
cells/well) were co-transfected with each plasmid expressing tumor suppressor-related protein, p53 (115), p73 (116,117), p73 (116,117), p21 (56,118),
Chk2 (119,120), Rb, ATM (121,122), or ATR (500 ng), and either pL1RP-EGFP or pL1RP(JM111)-EGFP (500 ng). Three days after transfection, retro-
transposition efficiency was determined by GFP FACS analysis. Experiments were done in triplicate and graph shows the mean (±SEM) percentage of
GFP positive cells (*P < 0.05). (B) Schematic representation of p21, p21 mutants (p21N and p21C), and p27. KID: kinase inhibitory domain, PCNA:
PCNA-binding domain, QT: glutamine threonine-rich domain. Protein expression levels of p21, p21N, p21C, and p27. 293T cells (2 × 105 cells/well) were
transfected with pcDNA3, pcDNA3p21 (56), pcDNA3p21N (56), pcDNA3p21C or pcCMXp27.Western blotting of the cell lysates with anti-p21, anti-27,
or anti--actin antibodies is shown. (C, D) KID is required for inhibitory effect on L1 retrotransposition. 293T cells (2× 104 cells/well) were co-transfected
with pcDNA3p21, pcDNA3p21N, pcDNA3p21C or pCMXp27 (100 ng) and either pYX014 (C) or pYX017 (D) (100 ng) in triplicate. Three days after
transfection, luciferase assays were performed. Graph shows the mean (±SEM) firefly luciferase activity normalized withRenilla luciferase activity in Rela-
tive Luminometer Units (*P< 0.05). (E) Inhibition of p21 expression by shRNA-producing lentiviral vector. Western blotting of cell lysates with anti-p21
or anti--actin antibodies is shown. (F, G) Enhancement of L1 retrotransposition efficiency in p21 knockdown cells. Control (ctrl) or p21 knockdown
(p21KD) 293T cells (2 × 104 cells/well) were transfected with either pYX014 (F) or pYX017 (G) (100 ng) in triplicate. 24h after transfection, luciferase
assays were performed, and results were plotted as described above (*P < 0.05).
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Figure 5. Incorporation of L1 ORF1p into HIV-1 virions. (A) 293T cells (2 × 105 cells/well) were co-transfected with 2 g of pcDNA3-HA-ORF1 or
pcDNA3-ORF1-HA and 2 g of pNL4-3 or pJR-FL. Western blotting of cell lysates or virion in the concentrated culture supernatants with anti-HA,
anti-HIV-1 p24, or anti--actin antibodies is shown. (B) HIV-1 accessory protein-independent incorporation of ORF1p into HIV-1 virions. 293T cells (2
× 105 cells/well) were co-transfected with 2 g of HIV-1 AD8 wild-type molecular clone (WT) (63) or HIV-1 mutants (Vif, Vpr, Vpu, or Nef)
and 2 g of pcDNA3-ORF1-HA. HIV-1 virions were then produced in the culture supernatants. Western blotting of HIV-1 in the concentrated culture
supernatants with either anti-HA or anti-HIV-1 p24 antibody is shown. (C, D) Incorporation of ORF1p does not affect the HIV-1 infectivity. TZM-bl cells
(1 × 105 cells/well) were inoculated with 100 l of the culture supernatants of 293T cells co-transfected with pNL4-3 (C) or pJR-FL (D), and pcDNA3-
HA-ORF1 or pcDNA3-ORF1-HA as shown in (A). 24 h post-infection, luciferase assays were performed. Graph shows the mean (±SEM) firefly luciferase
activity in Relative Luminometer Units (*P < 0.05). (E) L1 ORF1p does not affect the Tat-mediated HIV-1 transcription. 293T cells (2 × 104 cells/well)
were co-transfected with HIV-1 LTR-Luc (100 ng), pcDNA3-HA-ORF1 (100 ng), pcDNA3-ORF1-HA, and/or pcDNA3-Tat101-FLAG (123) (100 ng)
in triplicate. 24h after transfection, luciferase assays were performed, and results were plotted as described above (*P < 0.05). (F) L1 ORF1p does not
affect the Rev-mediated nuclear export function. 293T cells (2 × 104 cells/well) were co-transfected with pDM628 (47) (100 ng), pcDNA3-HA-ORF1 (100
ng), pcDNA3-ORF1-HA, and/or pcRev (47) (100 ng) in triplicate. 24 h after transfection, luciferase assays were performed, and results were plotted as
described above (*P < 0.05).
port function using the Rev-dependent luciferase-based re-
porter plasmid pDM628 (47,49). Our results showed that
ORF1p did not affect either Tat or Rev function (Figure 5E
and F).
Vpr and p21 do not suppress L1 transcription and ORF1p
expression
To determine whether Vpr and p21 suppress L1 mobility by
inhibiting theL1 promoter activity, we examinedL1mRNA
expression by real-time RT-PCR. Both p21 and Vpr did not
affect the level of L1 mRNA from the L1 5′UTR promoter
(pYX014) (Figure 6A). HIV-1 clones (R9 and NL4-3) en-
hanced L1 transcription two days post-transfection (Figure
6A). Similarly, Vpr did not suppress the level of endogenous
L1 mRNA (Figure 6B). Thus, Vpr and p21 may suppress
L1 mobility post-transcriptionally. Since Vpr is known to
enhance p21 promoter activity (86,87), we wished to con-
firm this regulation in 293T cells. Indeed, we observed that
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Figure 6. Vpr and p21 do not suppress L1 transcription. (A) The level of L1 ORF1 mRNA in 293T cells co-transfected with pYX014 and pcDNA3p21,
pCMX-Vpr96, pR9, or pNL4-3 was monitored by real-time LightCycler PCR two days post-transfection, respectively. Experiments were done in triplicate,
and graph shows the mean percentages (±SEM) of L1 ORF1mRNA normalized with ß-actin mRNA, with the pYX014 condition set at 100% (*P< 0.05).
(B) The level of endogenous L1 mRNA in 293T cells transfected with pCMX-Vpr96 was monitored by real-time LightCycler PCR. Primer pairs targeting
primate (L1PA - ORF1) or human (L1Hs – ORF1 and 5′UTR) L1 subfamilies were used. Experiments were done in triplicate, and graph shows the mean
percentages (±SEM) of L1 mRNA in presence of Vpr normalized with both ß-actin mRNA and the ‘no Vpr’ condition for each primer pair (*P < 0.05).
(C) Effect of Vpr on p21 promoter activity. 293T cells (2 × 104 cells/well) were co-transfected with pWAF1-Luc (100 ng) and pCMX-Vpr96 (100 ng)
in triplicate. 24h after transfection, luciferase assays were performed. Graph shows the mean (±SEM) firefly luciferase activity in Relative Luminometer
Units (*P < 0.05). (D, E) Vpr suppresses L1 retrotransposition efficiency in a p21-independent manner. p21 (p21KD) knockdown 293T cells (2 × 104
cells/well) were co-transfected with pCMX-Vpr96 (100 ng) and either pYX014 (D) or pYX017 (E) (100 ng) in triplicate. 24h after transfection, luciferase
assays were performed. Graph shows the mean (±SEM) firefly luciferase activity normalized with Renilla luciferase activity with the condition without
Vpr set to 100% (*P < 0.05).
Vpr weakly enhanced p21 promoter activity (Figure 6C).
To examine whether Vpr suppress L1 retrotransposition in
a p21-dependent manner, we used p21 knockdown 293T
cells. Our results showed that Vpr could strongly suppress
L1 retrotransposition even in p21 knockdown cells (Fig-
ure 6D and E), suggesting that Vpr suppresses L1 mobil-
ity in a p21-independent manner. To test whether Vpr and
p21 affect L1 transcription and L1-encoded protein expres-
sion, we used an anti-human ORF1 antibody (SE-6798)
(65). Vpr and p21 did not alter endogenous ORF1p expres-
sion (Figure 7A). Similarly, Vpr and p21 did not suppress
ORF1p when expressed from plasmids pJM101/L1.3 and
pJM105/L1.3, which respectively contain WT and ORF2p
RT-mutant (D702A) humanL1.3 element in a pCEP4 back-
bone vector (88) (Figure 7A and B). Moreover, Vpr did not
enhance endogenous p21 expression (Figure 7A). To test the
impact of Vpr on pCEP4 expression unit, we used the con-
trol backbone plasmid pCEP-GFP that expresses hrGFP
(89). Vpr did not affect hrGFP expression from pCEP4
when both proteins were co-expressed in 293T cells (Fig-
ure 7B). Thus, Vpr and p21 did not affect L1 transcription
and L1 ORF1p expression.
Vpr and p21 suppress L1 ORF2p-mediated reverse transcrip-
tion
To examine whether HIV-1 Vpr interacts with L1 ORF1p
and/or ORF2p, we performed immunoprecipitation and
immunofluorescence studies. We did not observe a co-
immunoprecipitation of Vpr with ORF1p (Figure 8A).
ORF1p was found in cytoplasmic foci (Figure 8B), consis-
tent with previous reports that ORF1p accumulates in cy-
toplasmic foci associated with stress granules (14,90). We
did not observe co-localization of Vpr with ORF1p. In con-
trast, we noticed that Vpr and p21 co-immunoprecipitated
with ORF2p by using TET-induced FLAG-tagged ORF2p
(pLD401) (91) in TET293T cells (Figure 8C). In addi-
tion, we confirmed that p21 co-immunoprecipitated with
FLAG-tagged ORF2p (pTMO2F3) (89) in 293T cells (Fig-
ure 8D). Furthermore, we observed a partial colocalization
of ORF2p with either Vpr or p21 (Figure 8E). Vpr alone
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/16/8454/5061969 by U
niversite and EPFL Lausanne user on 18 February 2019
8464 Nucleic Acids Research, 2018, Vol. 46, No. 16
Figure 7. Vpr and p21 do not suppress L1 ORF1p expression. (A)
The level of L1 ORF1p in presence of Vpr WT and H71R mu-
tant. 293T cells (2 × 105 cells/well) were cotransfected with 2 g of
pCEP-GFP, pJM105/L1.3 reverse transcriptase-deficient mutant (88), or
pJM101/L1.3 wild-type L1 (88), and 2g of pcDNA3-HA, pcDNA3-HA-
Vpr WT, pcDNA3-HA-Vpr H71R, or pcDNA3p21. Cells were cultured
for 4 days, lysed and subjected to western blot to analyze the expression
of ORF1p using anti-hORF1P antibody (SE-6798) (65). Western blotting
of the cell lysates with anti-Vpr, anti-p21, and anti--actin antibodies is
also shown, respectively. (B) Protein expression level of L1 ORF1p and
hrGFP in presence of Vpr WT and H71R mutant. 293T cells were trans-
fected with pJM105/L1.3 or pCEP-GFP, together with either pcDNA3-
HA or pcDNA3-HA-VprWT and cultured for the indicated time.Western
blotting of the cell lysates with anti-hORF1p, anti-Vpr, anti-GAPDH and
anti-hrGFP (240141; Agilent) antibodies is shown, respectively.
predominantly localized to nucleus and nuclear membrane
(Figure 8B), whereas Vpr partially colocalized with ORF2p
into cytoplasmic foci (Figure 8E). p21 partially colocalized
with ORF2p in the nucleus (Figure 8E). Thus, Vpr and p21
seem to interact with L1 ORF2p but not ORF1p, suggest-
ing a possibility that Vpr and p21 inhibit L1 retrotranspo-
sition through ORF2p-mediated activities. To test this pos-
sibility, we examined whether Vpr and p21 suppress the L1
reverse transcriptase (RT) activity by LEAP assay. For this
approach, we first enriched for L1RNP from transfect 293T
cell extracts, since ORF2p is characterized by a low level of
expression due to its unconventional translationmechanism
(14,92). L1 RNA assembles with ORF1p and ORF2p to
form RNP complexes in the cytoplasm from which ORF2p
RT activity can be detected. Indeed, we detected L1ORF1p
and ribosomal S6 proteins by western blot in the enriched
RNP fractions (Figure 9A). S6 protein is abundant in cellu-
lar RNP preparations. Interestingly, we noticed that low but
detectable amounts of Vpr and p21were present in theRNP
fractions when co-expressed with L1 (Figure 9A), suggest-
ing that Vpr and p21 may be part of L1 RNPs. However,
at this stage, the data presented are not sufficient to deter-
mine if these proteins actually form part of the L1 RNP.
In this context, ORF2p RT activity measured by LEAP as-
say was significantly reduced with Vpr WT or p21 (Figure
9B), indicating that Vpr and p21 strongly inhibit the L1 RT
activity. Consistent with the result of L1 retrotransposition
activity with Vpr H71R (Figure 3E and F), Vpr H71R had
a marginal effect on the ORF2 RT activity compared with
that of Vpr WT (Figure 9B). Altogether, Vpr and p21 seem
to restrict L1 retrotransposition through an inhibition of
ORF2p RT activity.
DISCUSSION
Several host cellular factors have been involved in the reg-
ulation of L1 mobility (12,21–27,91,93). In this study, we
have demonstrated that viral (Vpr) and cellular (p21 and
p27) cell cycle regulators restrict L1 mobility. Both p21 and
p27 belong to the Cip/Kip family of CDKkinase inhibitors
(CKIs) (73–77). p21 is the first reported cell cycle inhibitor,
blocking cell cycle at G1/S phase (73–75). p27 arrests the
cell cycle at G1/S phase (76,77). Vpr arrests the host cell cy-
cle at G2/M phase (53). Therefore, cell cycle control might
be important for L1 retrotransposition. In this regard, Shi
et al. previously reported that L1 retrotransposition was
strongly inhibited in cells arrested at G1, S, G2 or M phase,
indicating that cell division is required for L1 retrotranspo-
sition (94). However, the same study found that the levels of
L1 transcripts were strongly reduced in arrested cells, sug-
gesting that transcriptional inhibition is largely responsible
for reduced retrotransposition observed (94). In contrast,
both Vpr and p21 did not suppress L1 transcription (Fig-
ure 6A and B), indicating that Vpr and p21 inhibit L1 mo-
bility post-transcriptionally. This result is consistent with
studies reporting limited retrotransposition levels in cell cy-
cle arrested cells that could not be explained by reduced L1
transcription (95,96). It suggests that even if retrotranspo-
sition can occur in arrested cells, cell division can promote
L1 retrotransposition efficiency (95,96). This observation
is not in disagreement with other studies reporting events
of retrotransposition in non-dividing cells (96,97). On the
other hand, Mita et al. reported that ORF1p together with
ORF2p and L1 mRNA enters the nucleus during mitosis
and retrotransposition appears to occur mainly during S
phase, indicating a cell cycle bias for L1 retrotransposition
(98). Furthermore, recent studies reported that ATM and
p53, a master regulator of cell cycle, also regulate L1 mo-
bility (99–101), even though we observed no effect of over-
expression of ATM in L1 retrotransposition (Figure 4A).
Interestingly, PCNA, the polymerase -associated sliding
DNA clamp, interacts with L1ORF2p through a PCNA in-
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Figure 8. HIV-1 Vpr and p21 bind to L1 ORF2p. (A) Vpr does not bind to L1 ORF1p. 293T cells (2 × 105 cells/well) were co-transfected with 2 g of
pcDNA3-HA-Vpr and 2g of pcDNA3-FLAG-ORF1. The cell lysates were immunoprecipitatedwith anti-FLAG (M2) antibody, followed by immunoblot
analysis using anti-FLAG (M2) and anti-HA (HA-7) antibodies. (B) Subcellular localization of HA-ORF1p and EGFP-Vpr. 293T cells were co-transfected
with pcDNA3-HA-ORF1 (100 ng) and pEGFP-Vpr (100 ng). Cells were stained with anti-HA (HA-7) antibody and then visualized with Cy3-conjugated
anti-mouse antibody. Nucleus was stained with DAPI. Images were obtained using confocal laser scanning microscopy (FV1200, Olympus). (C) Vpr and
p21 bind to ORF2p. TET293T cells (2 × 105 cells/well) were transfected with pLD401 (91). Cells were incubated with 1 g/ml puromycin for 3 days
and then treated with 500 ng/ml doxycycline for 2 days. Then, the cells were transfected with either pcDNA3-HA-Vpr or pcDNA3p21. 2 days post-
transfection, the cell lysates were immunoprecipitated with anti-FLAG antibody, followed by immunoblot analysis using anti-FLAG, anti-HA, or p21
antibody. (D) p21 binds to ORF2p. 293T cells (2 × 105 cells/well) were transfected with pTMO2F3 (89). Three days post-transfection, the cell lysates were
immunoprecipitated with anti-FLAG antibody, followed by immunoblot analysis using anti-FLAG, and p21 antibodies. (E) Subcellular localization of
Vpr, p21, and/or ORF2p-FLAG. 293T cells were co-transfected with pTM02F3 (100 ng) and either pcDNA3-HA-Vpr (100 ng) or pcDNA3 p21 (100ng).
Cells were stained with anti-FLAG (M2) and either anti-HA (3F10) or anti-p21 antibodies and then visualized with Alexa596-conjugated anti-mouse
and either Alexa488-conjugated anti-rat or anti-rabbit antibodies. Nucleus was stained with DAPI. Images were obtained using confocal laser scanning
microscopy.
teracting protein (PIP) box (91). The interaction of ORF2p
with PCNA is critical for L1 retrotransposition (91). In this
regard, PCNA is known to bind to the C-terminal domain
of p21 (56), suggesting a possibility that p21 competes with
L1 ORF2p for the PCNA-binding, resulting in the repres-
sion of L1 retrotransposition. However, the C-terminal half
of p21, p21C, did not reduced L1 retrotransposition (Fig-
ure 3C and D), indicating that p21 restricts L1 retrotrans-
position in a PCNA independent manner. In this study, we
showed that p21 interacts with L1 ORF2p and inhibits the
ORF2p reverse transcriptase activity in LEAP assay (Fig-
ures 8 and 9).
We showed that the inhibitory effect of a mutant Vpr
(H71R), which is unable to arrest the cell cycle, was signif-
icantly reduced compared with that of wild-type Vpr (Fig-
ure 3E and F), suggesting that Vpr suppresses L1 mobil-
ity in a cell cycle dependent manner. Independent of cell
cycle control, we have demonstrated that Vpr restricts L1
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Figure 9. Vpr and p21 suppresses L1 reverse transcriptase activity. (A) Western blotting of human ORF1p, HA-Vpr, p21 or S6 protein as a loading
control in RNP prepared from 293T cells transfected with the indicated plasmids: pCEP4 and pcDNA3-HA (HA) empty vectors (–), pJM105/L1.3 and
pcDNA3-HA (–) or pJM101/L1.3 together with pcDNA3-HA (–), pcDNA3-HA-Vpr WT, pcDNA3-HA-Vpr H71R, or pcDNA3 p21. (–) Detection of
L1 RT activity by LEAP assay (top panel) and of L1 RNA (middle panel) or GAPDH RNA (bottom panel) by RT-PCR. LEAP assay was performed
with RNP prepared from cells transfected with indicated plasmids. PCR control denotes a control for the PCR step without cDNA. LEAP/RT control
denotes a control for RT step without RNP. RNP samples used in panel A and B are from the same replicate. The experiment was replicated three times
with similar results.
retrotransposition by inhibiting ORF2p-mediated reverse
transcriptase activity (Figure 9B). Moreover, despite lim-
ited levels of ORF2p detection, possibly due to unconven-
tional translational mechanism (14,92) or protein stability,
we found that Vpr coimmunoprecipitates with L1 ORF2p
but not ORF1p (Figure 8A, C and D). Vpr can also be
detected in cellular RNP fractions alongside with L1 (Fig-
ure 9A), providing additional circumstantial evidence that
Vpr associates with ORF2p and inhibits RT activity (Fig-
ure 9B). On the other hand, p21 has been involved in re-
striction of HIV-1 during reverse transcription (102–105).
Ribonucleotide reductase (RNR) increases the dNTP pool
andHIV-1 relies on cellular dNTPs for its reverse transcrip-
tion. p21 represses dNTP biosynthesis by down-regulating
the expression of the RNR2 subunit of ribonucleotide re-
ductase, resulting in the restriction of HIV-1 (104). Fur-
thermore, Pauls et al. recently reported that p21 regulates
a sterile alpha motif (SAM) and histidine/aspartic acid
(HD) domain-containing protein 1 (SAMHD1) (105). The
deoxynucleoside triphosphohydrolase SAMHD1 has been
identified as a novel myeloid cell specific HIV-1 restric-
tion factor (106–111). Indeed, SAMHD1 inhibits HIV-1 re-
verse transcription by depleting the intracellular dNTPpool
(111) and restricts L1 retrotransposition by inhibiting the
ORF2p-mediated L1 reverse transcription (112). Similarly,
we have demonstrated that p21 interacts with ORF2p (Fig-
ure 8C and D) and can also be detected in cellular RNP
fractions alongside with L1 (Figure 9A), resulting in inhibi-
tion of ORF2p RT activity (Figure 9B). Therefore, in HIV-
1-infected patient cells or tumor cells with overexpression of
p21, or a mutation in the N-terminus of p21 or p27, these
cell cycle regulators may potentially impact L1 retrotrans-
position.However, if p21 is overexpressed inHIV-1-infected
cells, p21 may inhibit both HIV-1 and L1 mobility. As Vpr
is known to enhance the p21 promoter activity (86,87), it
raised the possibility that Vpr transcriptionally induces the
p21, resulting in the suppression of L1 mobility. However,
we showed that Vpr did not accumulate endogenous p21 ex-
pression in 293T cells (Figure 7A) and Vpr could suppress
L1 retrotransposition even in p21 knockdown cells (Figure
6D and E), suggesting that Vpr suppresses L1 mobility in a
p21-independent manner.
Since endogenous retroelements such as L1, Alu, SVA,
and HERVs are abundant and constitute ∼45% of the hu-
man genome, they may influence the integrated exogenous
HIV-1 retroviruses, or vice versa. In this study, we demon-
strated that L1 ORF1p is incorporated into the HIV-1 viri-
ons (Figure 5), suggesting a possibility that infectious HIV-
1 particle might horizontally transmit L1 into target cells
as a vector. Another possibility is that the incorporated
ORF1p affects the HIV-1 infectivity. However, the incorpo-
ration of ORF1-HA into HIV-1 virion did not affect the
HIV-1 infectivity, except only HA-ORF1 moderately sup-
pressed the infectivity of NL4-3 but not JR-FL (Figure 5C
and D), even though similar amounts of ORF1p were in-
corporated into both NL4-3 and JR-FL virion (Figure 5A).
Since ORF1p is an RNA-binding and nucleic acids chap-
erone protein, we also examined whether ORF1p modu-
lates the HIV-1 Tat-mediated HIV-1 transcription or HIV-
1 Rev-dependent nuclear export function of HIV-1 RNA.
However, ORF1p did not affect either Tat or Rev func-
tion (Figure 5E and F), suggesting that ORF1p might not
bind and affect HIV-1 RNA. In this regard, we failed to
observe the interaction of ORF1p with HIV-1 RNA (data
not shown). Furthermore, we found that the incorporation
of ORF1p into HIV-1 virions was independent of HIV-1
accessory proteins including Nef, Vpr, Vpu and Vif, be-
cause the mutant viruses lacking the expression of each
viral gene still retained the ability to incorporate ORF1p
(Figure 5B). Since it has been indicated that several P-
body and stress granule components, such as APOBEC3G,
APOBEC3F andMOV10, are incorporated intoHIV-1 viri-
ons through an interaction with nucleocapsid protein (NC)
(78–82), ORF1p, a component associated to stress granule
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(14,90), also might be incorporated into virion through an
interaction withNC. To fully explain these phenomena, fur-
ther mechanistic studies are required. Jones et al. demon-
strated that the L1 DNA accumulates in the HIV-1 infected
cells (113). In this regard, we also observed that HIV-1 in-
fection slightly enhances the L1 transcription (Figure 6A).
In a previous study, Iijima et al. reported that extracellular
Vpr protein in the culture medium induces L1 retrotrans-
position (114). In contrast, we found that Vpr strongly sup-
presses L1 retrotransposition when co-expressed in the cell
(Figure 2). The cause for this discrepancy may be due to
technical differences and experimental strategies. Iijima et
al. only used recombinant Vpr protein in their experiments.
In contrast, we used Vpr-expressing plasmids to obtain in-
tracellular expression of Vpr in dividing cells. All tested
plasmids (pcDNA3-HA-Vpr, pCMXVpr96, pAIP-Vpr and
pEGFP-Vpr) could strongly suppress L1 retrotransposition
and LEAP assay showed that Vpr inhibits L1 RT activity
(Figure 9B). Except for the demonstration that Vpr inhibits
reverse transcription by ORF2p, the other proteins may be
inhibiting L1 indirectly or act on cell cycle to limit the ex-
pression of the reporter cassette.
Finally, if L1 actively jumps and inserts a new copy of
L1 in the integrated HIV-1 proviral locus or in genes essen-
tial for the infected cell survival, it will result in the destruc-
tion of HIV-1 or the infected cell. Therefore, we can specu-
late that HIV-1 may restrict L1 mobility to protect its own
genome and the genome of the infected cell from de novo
L1 insertional mutagenesis. Altogether, we suggested that
viral and cellular cell cycle regulators can negatively impact
L1 mobility through an inhibition of ORF2p reverse tran-
scriptase.
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